Capecitabine Tablets

Capecitabine is an oral chemotherapy drug with selective targeting effect on tumor cells. Capecitabine itself is non-cytotoxic and can be activated into cytotoxic 5-fluorouracil in tumor cells through a three-step enzyme chain reaction, thereby minimizing the damage of 5-fluorouracil to normal human cells.

Capecitabine

FDA approved for the treatment of metastatic breast cancer that is resistant to conventional therapies and for the treatment of metastatic colorectal cancer in combination with Taxotere for the treatment of advanced breast cancer.

The recommended dose is 2,500 mg/m2 per day, for two weeks, followed by a one-week break. The total daily dose should be taken twice a day, morning and evening, with water half an hour after meals.

Xeloda has fewer adverse reactions, and the following conditions may be related to it: Digestive system: The most common adverse reactions of Xeloda are reversible gastrointestinal reactions, such as diarrhea, nausea, vomiting, abdominal pain, gastritis, etc. Severe (grade 3-4) adverse reactions are relatively rare. Skin: Hand-foot syndrome occurs in almost half of the patients using Xeloda: manifested as numbness, insensitivity, paresthesia, tingling, painlessness or pain, skin swelling or erythema, desquamation, blisters or severe pain. Dermatitis and alopecia are common, but severe cases are rare. General adverse reactions: Fatigue is common, but severe cases are extremely rare. Other common adverse reactions are mucositis, fever, weakness, drowsiness, etc., but none of them are serious.

Patients with a history of severe side effects to Xeloda or hypersensitivity to fluoropyrimidines (metabolites of capecitabine) are contraindicated in using Xeloda.

Precautions for children: The safety and efficacy of capecitabine in patients under 18 years of age have not been confirmed.

Xeloda has been used in combination with a large number of drugs, such as antihistamines, NSAIDs, morphine, paracetamol, aspirin, antiemetics, H2 receptor antagonists, etc., without clinically significant side effects. Protein binding: Capecitabine has a low binding rate to serum proteins (64%). The possibility of interaction with drugs that are tightly bound to proteins through displacement cannot be predicted. Interaction with cytochrome P450 enzymes: In in vitro experiments, capecitabine was not found to affect human liver microsomal P450 enzymes.

Sealed storage

0.5 g

24 months